Core Laboratories Inc. key statistics and ratios

In fiscal 2025, Core Laboratories Inc. had return on equity of 11.6%, an operating margin of 10.7%, debt equal to 42.5% of equity and a current ratio of 2.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Core Laboratories Inc.: financial ratios, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	—	19.6%	21.5%	19.7%	20.7%	19.1%
Operating margin	9.6%	8.5%	10.7%	11.2%	10.7%	7.5%
Net margin	4.2%	4.0%	7.2%	6.0%	5.6%	3.0%
Free-cash-flow margin	4.9%	3.0%	2.8%	8.5%	4.9%	2.0%
Return on equity	12.3%	11.3%	17.9%	13.3%	11.6%	5.7%
Return on assets	3.4%	3.4%	6.3%	5.4%	5.1%	2.6%
Asset turnover	0.81	0.84	0.88	0.89	0.90	0.88
Current ratio	—	2.05	2.53	2.16	2.02	2.19
Debt to equity	0.0%	95.0%	73.8%	51.9%	42.5%	41.3%
Interest cover (operating income ÷ interest)	4.9x	3.6x	4.1x	4.7x	5.3x	3.5x
Effective tax rate	44.0%	34.4%	10.2%	30.4%	33.8%	43.8%
Capital spending as % of revenue	2.9%	2.1%	2.1%	2.3%	2.1%	2.8%
Free cash flow ÷ net income	116.8%	75.8%	38.7%	141.7%	87.0%	66.6%
Dividends ÷ net income	9.3%	9.5%	5.1%	6.0%	6.3%	11.9%
Dividends and buybacks ÷ free cash flow	43.8%	39.1%	28.6%	16.1%	55.4%	118.1%

US$ thousands unless shown otherwise. Fiscal quarters.

Core Laboratories Inc.: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	17.8%	19.5%	20.3%	22.0%	20.8%	16.2%	18.6%	20.4%
Operating margin	11.0%	3.6%	11.7%	15.6%	11.5%	1.5%	7.3%	9.1%
Net margin	5.7%	−0.1%	8.2%	10.6%	3.6%	−0.6%	4.8%	4.1%
Free-cash-flow margin	13.4%	3.1%	8.0%	4.8%	3.6%	0.4%	2.5%	1.3%
Current ratio	2.16	2.21	2.27	2.37	2.02	2.05	2.12	2.19
Debt to equity	51.1%	49.1%	47.7%	42.1%	41.5%	42.6%	41.8%	40.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 5 checks passed · September 30, 2026

What it owns · $594m

Short-term assets $225mLonger-term assets $368m

What it owes, and who funded it · $381m

Short-term liabilities $103mShareholders' equity $278m

Short-term assets cover short-term liabilities $225m of assets due within a year against $103m of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt $21m of cash against $112m of debt.
Debt below 40% of shareholders' equity Debt is 40% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $25m of operating cash flow against $112m of debt.
Operating profit covers interest at least five times over Operating income of $39m against $11m of interest.

From Core Laboratories Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CLB vs RNGR BOOM vs CLB CLB vs KLXE

More: Oil & Gas Equipment & Services stocks compared, Energy sector, rankings of US companies

Figures from Core Laboratories Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Core Laboratories Inc.